Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Bonti is a clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin products for therapeutic and aesthetic applications. We are developing a first-in-class pipeline of proprietary product candidates derived from botulinum neurotoxin serotype E, or BoNT/E. BoNT/E has a validated mechanism of action similar to that of currently approved products derived from botulinum...
Bonti is a clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin products for therapeutic and aesthetic applications. We are developing a first-in-class pipeline of proprietary product candidates derived from botulinum neurotoxin serotype E, or BoNT/E. BoNT/E has a validated mechanism of action similar to that of currently approved products derived from botulinum neurotoxin serotype A, or BoNT/A.

List your booth number for exhibitions, ask us